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ABSTRACT 
Infections with Coxsackieviruses are common and in most cases the infection is 
asymptomatic and efficiently cleared. On rare occasions, however, an infection can lead to 
severe diseases including myocarditis, hepatitis and pancreatitis. Infections with 
Coxsackieviruses have also been implicated in the pathogenesis of type 1 diabetes (T1D). 
Upon a virus infection, the innate immune response plays an important role in restricting viral 
replication and further dissemination to susceptible organs. An inability to mount an 
appropriate immune response may increase virus-induced damage. This thesis focuses on the 
cross-talk between host and Coxsackievirus. The aims were to identify mechanisms by which 
the host restricts infection and to unravel strategies used by the virus to evade the host 
immune response.  
We identified that the intracellular virus receptor melanoma differentiation associated factor 5 
(MDA5) has an important role in the host response to a Coxsackievirus infection. Absence of 
this receptor led to a decreased ability to control viral replication, which resulted in severe 
tissue damage and increased mortality. Polymorphisms in interferon induced with helicase C 
domain (IFIH1), the gene encoding MDA5, regulate the risk for T1D development, further 
implicating the involvement of Coxsackieviruses in T1D pathogenesis. Studies in this thesis 
showed that the Ala946Thr polymorphism in IFIH1 regulates how human pancreatic islets 
respond to a Coxsackievirus infection. The predisposing allele 946Thr was associated with 
lower induction of interferons (IFNs) and IFN-inducible genes. It has previously been shown 
that type I IFNs play an important role in the host defense against Coxsackievirus. Type III 
IFNs are a recently described group of IFNs that mainly act on epithelial cells and provides 
protection against virus infection. This thesis established a novel role for the type III IFNs in 
inducing an antiviral state in infected human pancreatic islets. Moreover, it demonstrated that 
type III IFNs protect primary human cells, inlcuding pancreatic islets and hepatocytes, from a 
Coxsackievirus infection. Due to the potent antiviral effect of IFNs, most viruses have 
developed mechanisms to inhibit their actions. In this thesis, strategies utilized by 
Coxsackieviruses to inhibit the induction of type III IFN were identified, which further 
underlines the importance of this group of IFNs in controlling a Coxsackievirus infection.  
The findings presented in this thesis further our understanding of how the host recognizes and 
combats a Coxsackievirus infection, and also describe evasion strategies used by the virus to 
inhibit these protective mechanisms. The studies also demonstrate that a polymorphism in 
IFIH1 affects the ability of human pancreatic islets to respond to a Coxsackievirus infection. 
A better understanding of the host-pathogen interactions may help in the development of 
therapeutic strategies to reduce the severity of Coxsackievirus infections. 
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1 INTRODUCTION 
To strive for survival all living organisms have developed mechanisms to defend themselves 
from predators. The constant pressure from microorganisms has lead to the development of 
protective mechanisms, collectively known as the immune system. The immune system is 
typically divided in two parts - the innate immune system which can be found in most 
organisms and reacts in a non-specific manner, and the adaptive immune system that is only 
found in vertebrates and provides long lasting protection against microbes. In parallel with 
the evolution of the immune system, invading microorganisms have also been under selective 
pressure and have therefore developed ways to evade the immune response. In this thesis, I 
have studied the interactions between the innate immune system and an infective pathogen 
namely enterovirus. The aim has been to further our understanding of how the host’s innate 
immune system recognizes enteroviruses and combats the virus infections. In addition, the 
aim was to decipher evasion strategies used by enteroviruses to circumvent the innate 
immune responses. A brief introduction to the field is provided to further the understanding 
of the concepts presented in the five papers (Paper I-V) that this thesis is based on.  
1.1 THE INNATE IMMUNE RESPONSE 
The innate immune system is the first line of defense against invading pathogens. Responses 
are immediate, within hours, and important for both limitation of viral spread and the 
orchestration of the adaptive immune response that follows. Several different arms combine 
to comprise the innate immune system, including physical barriers such as the skin and 
mucosal surfaces, cellular components like natural killer (NK) cells and phagocytic cells and 
also inflammatory molecules such as complement and interferons (IFNs) [1]. To enable such 
an immediate response, the innate immune system responds in a non-specific manner. 
Induction of the innate immune response relies on the sensing of pathogen-associated 
molecular patterns (PAMPs) by pattern recognition receptors (PRRs). Activation of PRRs 
results in the production of cytokines and chemokines. Most cells express PRRs and can 
produce IFNs, which act in both an autocrine and a paracrine manner [2, 3].  
1.1.1 Recognition of a viral infection 
Recognition of the invading pathogen is imperative to mount a proper immune response. It is 
therefore not surprising that the immune system has evolved such a diverse array of receptors 
for efficient pathogen sensing. Two receptor families serve as the main sensors of viral 
infection, namely the toll like receptors (TLRs) and RIG-I like receptors (RLRs) [4].  
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Receptor Localization Ligands 
TLR1 Cell surface Triacyl lipopeptides 
TLR2 Cell surface Peptidoglycans, hemaglutinin 
TLR3 Endosome ssRNA virus, dsRNA virus 
TLR4 Cell surface Lipopolysaccharide 
TLR5 Cell surface Flagellin 
TLR6 Cell surface Diacyl lipopeptides 
TLR7 Endolysosome ssRNA virus 
TLR8 Endolysosome ssRNA from virus 
TLR9 Endolysosome dsRNA virus 
TLR10 ? ? 
RIG-I Cytoplasm ssRNA virus, short poly I:C,  
short dsRNA with 5’ triphosphate end  
MDA5 Cytoplasm Positive-sense ssRNA virus, long poly I:C 
Table 1. TLRs and RLRs, cellular localization and ligands. Adapted from [5-7]. 
1.1.1.1 Endosomal and extracellular recognition 
TLRs are evolutionary conserved and respond to an array of microbial products (Table 1). 
They are expressed on the cellular surface as well as in intracellular vesicles of both immune- 
and non-immune cells. Activation of TLRs leads to the secretion of inflammatory cytokines, 
IFNs and anti-microbial peptides [8, 9]. Recognition by TLRs also leads to maturation of 
dendritic cells (DCs), which have the ability to initiate and modulate the adaptive immune 
response [10]. In humans, 10 TLRs have been identified. The functions of TLRs 1-9 have 
been well characterized, whereas the role of TLR10 remains unclear. A subset of TLRs 
namely, TLR3, TLR7, TLR8 and TLR9 has been demonstrated to have an involvement in the 
sensing of viral infections [5, 11]. TLR3 is activated by double stranded (ds)RNA, which is 
either expressed by viruses carrying a dsRNA genome or produced as an intermediate during 
replication [12]. It has been shown that viruses including Influenza A virus and West Nile 
virus are recognized by TLR3 [13, 14]. TLR3 can also serve as sensor for polyinosinic-
polycytidylic acid (poly I:C), a synthetic viral mimic [15]. In addition, TLR2 and TLR4 have 
been implicated in recognition viruses including Cytomegalovirus and Coxsackeivirus [16, 
17]. 
Stimulation of TLRs leads to the induction of IFNs via activation of the transcription factor 
IFN regulatory transcription factor 3 (IRF3) and nuclear factor kappa light chain enhancer of 
activated B-cells (NF-κB). According to the use of adaptor protein, TLRs can be divided into 
two groups. All TLRs, with the exception of TLR3, induce IFN-expression via myeloid 
differentiation factor 88 (MyD88). Whereas, TLR3 and TLR4 signals via TIR-domain-
containing adapter-inducing IFNβ (TRIF) [5, 11].  
1.1.1.2 Cytoplasmic recognition 
While the TLRs survey the extracellular and the endosomal compartments in the cell the 
cytoplasm is patrolled by RNA helicases. The RLRs contains three members, retinoic acid-
inducible gene 1 (RIG-I), melanoma differentiation associated protein 5 (MDA5) and 
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laboratory of genetics and physiology 2 (LGP2) [18]. RIG-I and MDA5 contain a DExD/H-
box helicase domain essential for dsRNA binding and two N-terminal caspase recruitment 
domains (CARDs) that are important for downstream signaling (Figure 3) [19, 20]. Binding 
of viral RNA by RIG-I and MDA5 leads to conformational changes in the proteins, which 
leads to exposure of CARDs and interaction with the adaptor protein interferon-β promoter 
stimulator 1 (IPS1, also knows as MAVS, CARDIF and VISA) [21-24].  
RLRs are important sensors of various RNA viruses, however they have different preferences 
in the RNA patterns that they bind. RIG-I recognizes RNA bearing a 5’ triphosphate end [25-
28], as well as short dsRNA stretches [29]. MDA5 on the other hand, cooperatively senses 
long dsRNA sequences and poly I:C [29, 30]. Because of the different ligand specificities 
these two receptors recognize different viruses. A wide variety of viruses including members 
of the paramyxoviridae-, orthomyxoviridae- and rhabdoviridae-family are sensed by RIG-I 
[18, 25, 30, 31], whereas MDA5 recognizes viruses belonging to the Picornaviridae family, 
such as encephalomyocarditis virus (EMCV) and Coxsackievirus [30, 32-34]. In addition, 
both RIG-I and MDA5 are required for the detection of some viruses such as West Nile virus 
and Dengue virus [31].  
To date, the role of LGP2 during virus infections is not clear. LGP2 can bind RNA, [18], but 
it lacks the CARDs that are important for the interaction with downstream molecules and 
therefore, cannot induce IFNs in a similar manner as RIG-I and MDA5. Initial studies 
suggested that LGP2 functioned as a negative regulator of RIG-I- and MDA5-signaling [18, 
35]. However, more recent studies however, have indicated that LGP2 rather acts as a 
positive regulator [36, 37]. Further studies are required to elucidate the role of LGP2 in 
antiviral defense. 
1.1.2 Interferons 
IFNs were discovered by Isaacs and Lindenmann in 1957 as proteins that, as the name 
implies, interfere with viral replication [38]. Since then, these macromolecules have been 
extensively studied and besides their inhibitory effects on viral replication, their range of 
functions also encompasses both anti-proliferative and immunomodulatory properties [39, 
40]. IFNs are typically classified into in three groups based on their sequence homology and 
receptor specificity; type I IFNs, type II IFNs and the type III IFNs. The type I IFNs comprise 
multiple IFNα subtypes and various single isoforms of IFNβ, -ε, κ, -δ, -ω, -τ and –ζ. IFNα 
and β have been widely recognized for their importance in combating virus infections, 
whereas the role of the other type I IFN members is less well known [41, 42]. Type II IFN 
consists of only one member, IFNγ. IFNγ is mainly produced by immune cells such as 
activated NK cells and T cells and its main effector function is to modulate of the immune 
response [43]. The type III IFNs are the most recently added group and consist of IFNλ1 (IL-
29), IFNλ2 (IL-28a), IFNλ3 (IL-28b) [44, 45]. A fourth member, IFNλ4, has been added to 
the family however the expression of this cytokine is only found in a fraction of the 
population [46]. The type III IFNs have a greater structural similarity to the cytokines that 
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belong to the IL-10-family, however their function and antiviral properties resemble those of 
IFNα and IFNβ [2, 47].  
 
Figure 1. Model for cellular sensing of Coxsackievirus and the induction of IFNs. 
1.1.2.1 Induction of type I and III interferons 
Virtually all cells have the ability to express IFNs, although the magnitude and timing of 
expression is dependent on cell type and stimulus [48]. During a viral infection, plasmacytoid 
DCs (pDCs) are generally considered the major IFN-producing cell and they can express both 
type I and type III IFNs [48, 49]. In the absence of viral infection or any other pathogen the 
expression of the IFNs is negligible. However after their induction, the expression is tightly 
regulated through negative feedback loops to limit tissue damage [50, 51].  
Expression of type I and type III IFNs is induced after recognition of pathogens by PRRs, as 
described in section 1.1.1. The subsequent signaling leads to the activation of transcription 
factors including IRF3, IRF7, NF-κB and activator protein -1 (AP-1), which bind positive 
regulatory domains (PRDs) in the promotor region of IFN-genes [52]. After binding to the 
PRDs, the transcription factors assemble into a complex known as the enhancesome that 
regulates the transcription of IFNs [52]. Expression of IFNβ requires promotor binding of 
NF-κB, ATF-2/c-Jun, and IRF3 (or IRF7) while the expression of IFNα is dependent on 
IRF7. In parenchymal cells, all of these transcription factors are constitutively expressed 
except IRF7, which is induced in a positive feed back loop by IFNs. Due to its dependency 
on IRF7, the expression of IFNα upon a virus infection is delayed. This is in contrast to the 
expression of IFNβ, which is immediate upon a viral infection [53]. In DCs, however, IRF7 is 
constitutively expressed and they can rapidly express large amounts of IFNs [53, 54] 
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Regulation of type III IFN expression somewhat differs from that of type I IFNs. Initial 
studies found that IFNλ1 showed a similar regulation and expression pattern as IFNβ, while 
IFNλ2 and IFNλ3 were expressed with delayed kinetics and displayed a dependence on IRF7, 
similar to IFNα [55, 56]. More recent studies have found that IRF3 and/or NF-κB can 
separately bind to regions outside of the type III IFN promotors [57] and independently 
induce expression of the type III IFNs [57-60]. In addition, infection with respiratory 
syncytical virus preferentially induces type III IFNs over type I IFNs [61], further supporting 
the case that expression is differently regulated.  
1.1.2.2 Interferon signaling and induction of an antiviral state 
Upon release, IFNs bind to distinct cell surface receptors. Type I IFNs bind to the IFNα 
receptor (IFNAR), a ubiquitously expressed receptor composed of IFNAR1 and IFNAR2 
subunits [3]. Type III IFNs exert their biological effect through the IFNλ-receptor (IFNλR), 
which consists of two subunits: IFNλR2 and IL-10R [44, 45]. In contrast to IFNAR, the 
IFNλR shows a restricted tissue distribution and is mainly expressed on specific immune 
cells and epithelial cells [62, 63]. Despite the use of different receptors, type I and type III 
IFNs induces the same signalling pathways and consequently induce similar types of 
biological activities [64-66] and Paper III. Binding of the IFNs to their respective receptor 
activates Janus activated kinases 1 (Jak1) and tyrosin kinase 2 (Tyk2). Activation of these 
kinases leads to the phosphorylation and activation of signal transducers and activators of 
transcription 1 (STAT1) and STAT2. STAT1/STAT2 dimers associate with IRF9 to form the 
IFN stimulated gene factor 3 (ISGF3) complex, which initiates the transcription of interferon 
stimulated genes (ISGs) [67].  
IFNs display antiviral properties that can be attributed to at least two distinct effects. The 
immunomodulatory function of IFNs is important for inducing the adaptive immune system 
and helps to clear the virus infection [68]. In addition, IFNs can induce an antiviral state, 
which prevent the cells from becoming infected and is therefore an important event for 
controlling a virus infection. The antiviral state includes the upregulated expression of over 
hundreds of genes [69], however, the function of many of the expressed proteins is not clear. 
One of these genes with a proven antiviral effect is 2´5 oligodenylate synthetase (OAS). 
Upon binding to dsRNA, OAS activates RNaseL, which leads to degradation of both viral 
and cellular RNA resulting in inhibition of viral replication [70]. OAS/RNaseL is important 
in the antiviral defense against Coxsackievirus as mice lacking the expression of RNase L 
fails to restrain virus replication and succumb early to the infection [71]. OAS/RNaseL has 
also been shown to have a protective effect upon infection with West Nile virus [72]. The 
family of Myxovirus resistance protein (Mx), consisting of MxA and MxB, has also been 
demonstrated to have important antiviral properties [73, 74]. Studies have shown that MxA 
restricts influenza virus and La Crosse virus replication [75, 76]. Moreover, over-expression 
of MxA reduces Coxsackievirus replication [77]. One of the earliest expressed ISGs is IRF7, 
which act as transcription factor potentiating IFN signaling [53]. IRF7 is also important for 
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the induction of IFNα as described in section 1.1.2.1. In addition to these ISGs, PRRs such as 
RIG-I and MDA5 are also induced in response to IFN [66, 78] and Paper III.  
1.1.2.3 Antiviral activity of type III interferons 
The type III IFNs are to a large extend similar to the type I IFNs. As discussed above, the 
signaling cascades induced by type I IFNs and type III IFNs are the same. Furthermore, type I 
IFNs and type III IFNs are often co-expressed and the protective effect is to a large extent 
overlapping [44, 45, 79]. Studies have shown that type III IFNs have been shown to protect 
against a wide array of viruses including encephalomyocarditis virus (EMCV) and vesicular 
stomatitis virus [44, 45]. Moreover, type III IFNs block infection with hepatitis B virus, 
hepatitis C virus and influenza A virus [62, 80-83].  
The most striking difference between type I IFNs and type III IFNs is the selective expression 
of the IFNλR on epithelial cells, which suggests that the type III IFNs are important for viral 
defense at the mucosal surface [62, 63]. Indeed, several studies have shown that type III IFNs 
protect epithelial cells originating in the intestine, lung and vagina from virus infection [82, 
84-86]. Interestingly, type III IFNs play a non-redundant role in protecting the epithelial cells 
in the small intestine from Rotavirus infection [85].  
In humans, type III IFNs also play a role in protecting hepatocytes against virus infection. 
Hepatocytes are epithelial like cells and respond well to type III IFNs [80, 86-88] and Paper 
IV. Pretreatment with type III IFNs protect hepatic cell lines and hepatocytes against HCV 
[83, 88] and Coxsackievirus infection [86] and Paper IV. Moreover, the type III IFNs are 
currently being clinically tested as a treatment against HCV infection [89, 90].  
1.2 ENTEROVIRUS 
Enteroviruses belong to the Picornaviridae family and they are currently divided into 12 
species named Enterovirus A-H and -J, as well as Rhinovirus A-C [91]. All enteroviruses are 
non-enveloped single-stranded RNA viruses that contain a small genome of approximately 
7500 bases [92].  
1.2.1 Coxsackievirus group B 
The first Coxsackievirus were isolated from two paralyzed children more than 60 years ago 
in the town of Coxsackie [93]. Later, several serotypes were identified and the 
Coxsackieviruses were divided into groups A and B based on pathogenicity [94]. Nowadays, 
Coxsackievirus group B (CVB) consists of six serotypes (CVB1-6) that belong to the 
enterovirus B genus [91]. Infections with CVBs are commonly encountered, especially 
during the neonatal period and childhood. The primary mode of infection is via the fecal oral 
route and to a lesser extent, via the respiratory route. Most infections with CVB are 
asymptomatic or associated with mild flu-like symptoms, however they can on rare occasions 
disseminate to other organs and cause severe conditions such as myocarditis, meningitis and 
hepatitis [92]. In addition, infections with CVB have also been associated with the 
development of type 1 diabetes (T1D) [95].  
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1.2.2 Coxsackievirus lifecycle 
The main receptor required for cellular entry of the CVBs is the coxsackie and adenovirus 
receptor (CAR) [96, 97]. However, decay accelerating factor (DAF) has been proposed as 
attachment receptor for some serotypes [98-100]. After entry, the virus is uncoated and the 
positive sense RNA is immediately translated. Translation of cellular RNA involves the 
recognition of a 5’cap, however the Coxsackievirus genome lacks this structure. Instead, a 
viral protein known as VpG is attached to the 5’end, which has been shown to be important 
for initiation of RNA-synthesis. Translation of the viral RNA therefore occurs in a cap-
independent manner via intracellular replication entry sites (IRES). Upon translation, the 
genome is made into a single polyprotein, which is cleaved into structural proteins (viral 
protein (VP), 1-4) and non-structural proteins (2A-C, 3A-D) by the virally encoded proteases 
2A and 3C (Figure 2). The structural proteins make up the viral capsid whereas the non-
structural proteins are mainly involved in synthesizing new viral RNA [101]. In addition, the 
non-structural proteins can also interfere with cellular processes and are known for shutting 
off cellular translation as well as inhibiting the induction of an immune response [102-106] 
and Paper V.  
Viral replication takes place in the cytoplasm on the outer surface of membraneous vesicles 
[101]. The first step in viral replication involves the synthesis of a negative complementary 
strand, which serves as a template for the production of positive RNA-strands. After 
assembly of new viral particles, the virus is released from the cell through cellular lysis, 
however non-lytic mechanisms have been suggested [107, 108].  
 
 
Figure 2. Coxsackievirus genome and polyprotein. Adapted from [109]. 
 
 
VP2 VP4 VP3 VP1 2A 3A 2C 3B 3C 3D 2B 
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1.3 HOST-ENTEROVIRUS INTERACTIONS 
1.3.1 Detection of Coxsackievirus and the role of interferons 
Both TLRs and RLRs have been shown to play a role in recognizing CVB. Among the TLRs, 
TLR3 seem to play the most essential role as demonstrated that mice who lack TLR3 
expression show a heightened mortality after infection with CVB compared to wild type mice 
[110, 111]. Abston et al have also demonstrated that expression of TLR3 is protective against 
CVB-induced myocarditis [112]. In addition, the expression of TRIF (the adaptor protein for 
TLR3 signaling, Figure 1) is important in controlling CVB3 replication in the heart [113]. 
Further supporting an important role for TLR3 is the finding that two SNPs in TLR3 are 
associated with the development of enterovirus-induced myocarditis [114]. Additional TLRs 
with a suggested involvement in Coxsackievirus recognition are TLR4, TLR7 and TLR8. 
TLR4 has been proposed to sense CVB in human pancreatic cell lines [17], whereas TLR7 
and TLR8 have been implicated in CVB recognition in pDCs and cardiac cells respectively 
[115, 116]. 
RLRs are also involved in the sensing of Coxsackievirus. Since Coxsackieviruses do not 
carry a 5’ triphosphate (the ligand for RIG-I) the focus has mainly been on the role of MDA5. 
Early studies showing that the sensing of EMCV (belongs to the family of Picornaviridae) 
was dependent on MDA5 suggested that Coxsackieviruses may also be recognized by this 
receptor [30]. This hypothesis was further supported by a study performed by Wang et al and 
our results presented in Paper I [33, 34]. Both studies showed that in the absence of MDA5, 
mice have an increased mortality upon CVB infection. Further supporting a role for MDA5 in 
sensing CVB, is the finding that mouse embryonic fibroblasts (MEFs) lacking MDA5 or 
IPS1 (the adaptor protein used by MDA5, Figure 1) are unable to produce IFNβ in response 
to transfection with CVB [32]. Of additional interest to the studies performed in this thesis is 
the finding that several SNPs in IFIH1 have been associated with the development of T1D, 
which is further described in section 1.4.1.3 of this thesis. 
An intact innate immune response is critical for restricting viral replication and promoting 
host survival after a Coxsackievirus infection. The protective role of the type I IFNs has been 
demonstrated in vivo using mice that are unable to respond to type I IFNs [117, 118] or are 
deficient in IFNβ [119]. These mice showed an increased susceptibility to Coxsackievirus 
infection and the severity of disease was much higher compared to wild type animals. In vitro 
studies also support a protective role for type I IFNs in Coxsackievirus infections [78, 120]. 
The protective effect of IFNs is suggested to be mediated largely by proteins with antiviral 
activity such as protein kinase-R (PKR), RNaseL and inducible nitric oxid synthase (iNOS). 
Indeed, mice lacking these genes succumb to an infection with Coxsackievirus [71, 121, 
122]. In addition to the type I IFNs, type III IFNs also induce the expression of antiviral 
proteins and can mediate protection against virus infections [44, 66, 86, 123]. In Papers III 
and IV, we describe a novel finding that type III IFNs also has a protective effect during 
Coxsackievirus infections. 
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1.3.2 Coxsackievirus evasion strategies to evade the innate immune 
response 
Coxsackieviruses have developed multiple mechanisms to counteract the innate immune 
response. By targeting several pathways, the virus can ensure that detection and the 
subsequent induction of IFNs is avoided or limited. Some of these alterations do not just 
affect the production of IFNs, but have a more global effect on the host’s cellular machinery. 
The Coxsackievirus proteases 2A and 3C have been shown to cleave eukaryotic initiation 
factor 4G (eIF4G) and poly A-binding protein (PABP) [103-105], two proteins important for 
translation initiation [124]. In addition, it has been demonstrated that the non-structural 
proteins 2B, 2BC and 3A interfere with endoplasmatic reticulum (ER) to Golgi transport 
leading to inhibition in protein secretion [125, 126]. Coxsackieviruses also restrict the 
induction of IFNs by targeting events that occur before translation. By targeting MDA5 and 
IPS1, the virus inhibits IFN-induction via the RLR pathway [102, 106] and Paper V. In a 
similar manner, induction of type I IFNs via TLR3 is blocked by reducing the expression of 
TRIF [106] and Paper V. Coxsackieviruses have also been found to interfere with the 
activation of the transcription factor NF-κB [127, 128], although it remains to be established 
whether this affects the induction of IFNs. 
The fact that Coxsackieviruses have developed multiple evasion strategies to interfere with 
the production of type I IFNs emphasizes the importance of this group of cytokines in 
combating Coxsackievirus infection. Our findings in Paper III and IV show that type III 
IFNs are also important in suppressing Coxsackievirus replication [66, 86], however whether 
the type III IFNs were also inhibited during infection with Coxsackievirus has not been 
investigated and was the focus of Paper V.  
1.4 TYPE 1 DIABETES 
T1D is a chronic disease characterized by a loss of functional insulin producing beta cells 
resulting in an inability to correctly regulate blood glucose levels. There is currently no cure 
for the disease and it is only controlled by life long administration of exogenous insulin. 
Manifestation of disease usually occurs during childhood or adolescence but can also develop 
in adults [129]. The incidence varies around the world ranging from 0.1 cases in 100 000 
individuals in low incidence countries such as Venezuela and up to 60 cases per 100 000 
individuals in countries with a high incidence including Finland and Sweden [130-133]. It is 
particularly important to note that there has been a rapid increase in the incidence during the 
past decades, especially among the young [131, 133]. T1D is a multifactorial disease 
resulting from a complex network of genetic and environmental factors [134]. It is considered 
to be an autoimmune disease based on the presence of predisposing HLA class II haplotype 
genes in the majority of cases together with the presence of autoreactive B- and T-cells [129]. 
However, how immunological tolerance to beta cell is broken and how beta cells are 
destroyed remains elusive.  
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1.4.1.1 The islets of Langerhans 
The pancreas is composed of exocrine and endocrine cells, which have two main functions, 
namely the digestion of ingested food (exocrine) and the regulation of glucose metabolism 
(endocrine). The exocrine cells produce digestive enzymes and make up the major volume of 
the organ. The endocrine cells produce hormones and are gathered in small clusters called the 
islets of Langerhans, which are scattered throughout the exocrine tissue. In total, the islets 
make up 1-2% of the total pancreas mass, each containing around 1000 cells. The islets 
mainly consist of five different cell types: alpha cells, beta cells, delta cells, epsilon cells and 
pancreatic polypeptide (PP) cells. Beta cells are the most abundant cell type and respond to 
elevated glucose concentrations through the release of insulin. Alpha cells are responsible for 
producing glucagon, which as oppose to insulin increase the glucose concentrations in the 
blood. Delta cells and epsilon cells produce somatostatin and ghrelin respectively and have 
regulatory functions. PP cells produce pancreatic polypeptide [135].   
1.4.1.2 Genetic factors  
Susceptibility to T1D is largely inherited and more than 50 genes have been linked to the 
development of the disease [134]. A common factor among many of these genes is that they 
play a role in modulating the immune response in one way or another and also, many of them 
are expressed by the beta cells themselves. The predominant genetic risk factors are the HLA 
class II genes [136]. However, genome wide association studies have, during the past decade, 
identified several additional genes, which contribute to disease susceptibility [134]. Presence 
of a susceptibility gene does not automatically lead to the development of T1D, however 
having multiple predisposing genes can increase risk [137].  
IFIH1 
The function of MDA5 as a viral sensor is important for the induction of IFNs and is 
described in section 1.1.1.2. Interestingly, several polymorphisms in the gene encoding IFIH1 
have been associated with T1D [138, 139]. These findings have been confirmed in several 
other populations [140-144], however are not valid in all [142, 145, 146]. Moreover, an 
association between polymorphisms in IFIH1 and other diseases with an autoimmune 
background such as systemic lupus erythematosus (SLE) [147, 148], psoriasis [149] and 
autoimmune thyroid disease [150] has also been found. The most common single nucleotide 
polymorphism (SNP) is the Ala946Thr (rs1990760). Among Europeans, threonine (Thr) is 
most common allele and the frequency in the British population is approximately 65% [138, 
139, 141, 151]. Presence of Thr at codon 946 in IFIH1 is associated with an increased risk of 
developing T1D, whereas alanine (Ala), the ancestral amino acid is linked to protection 
against the disease [139]. In addition, two polymorphisms have been identified, Glu627X 
(rs3574460) and Ile923Val (rs35667974) which are associated with protection against T1D 
[151]. However the presence of the protective alleles among the population is rare, less than 3 
%. Exactly how polymorphisms in IFIH1 alter the risk of developing T1D remains to be 
established in detail. Studies performed so far have suggested that the SNPs in IFIH1 alter 
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expression levels and function of the protein [142, 151, 152]. How polymorphisms in IFIH1 
affect the response to enterovirus is however, not yet known and we aim to address this 
question in Paper II. 
 
Figure 3. Structure of the IFIH1 gene, positions of polymorphisms associated with T1D are 
indicated. Adapted from [153] 
1.4.1.3 Environmental factors -a role for enteroviruses? 
The rapid increase in the number of T1D cases during recent years coupled with a relatively 
low concordance rate between monozygotic twins [154, 155] suggests that environmental 
factors also play a role in disease development. Several factors have been proposed such as 
dietary components [156], vitamin D status [157] and a lack of exposure to microbes (the 
“hygiene hypothesis”) [158]. In addition, numerous studies have linked virus infections to the 
development of T1D and several viruses have been proposed, including rotavirus [159], 
Rubella virus [160] and enterovirus [161]. The strongest associations are found with the 
enteroviruses and especially with Coxsackieviruses [161-163]. This link is supported by 
several epidemiological studies and clinical observations [158, 164-167]. An association has 
also been found between the appearance of autoantibodies and enterovirus infections [165, 
168]. Moreover, enterovirus has been found more often in the pancreas and intestine of 
patients with T1D compared with healthy control group [163, 167, 169-171]. In vitro, 
enteroviruses have a tropism for the pancreatic beta cells and can cause severe damage to the 
cells [172]. Although many studies point towards an association between enteroviruses and 
development of T1D, there are some studies that fail to find a relationship [173, 174]. 
Several mechanisms have been proposed to explain how an enterovirus infection would cause 
T1D, including direct infection of the beta cell, molecular mimicry and bystander activation 
[175]. A direct infection of beta cells is the mechanism that has been most extensively studied 
and is supported by the studies showing that enterovirus can replicate in islets in vitro [66, 
78] and Paper III, which result in severe cellular damage [172].  Direct infection of beta 
cells has been proposed to be involved in the progression to fulminant diabetes. This subset 
of T1D is characterized by a rapid onset and a near complete loss of beta cells. In contrast to 
T1D, autoimmunity is believed to play a less prominent role in fulminant diabetes [176, 177]. 
Direct infection of beta cells can also lead to a persistent infection, which is supported by in 
vitro studies showing that Coxsackieviruses can persist in beta cells for several months [120]. 
CARDs Helicase domain C-terminal domain 
IPS1 binding ATP binding Nucleic acid binding 
Glu627X His843Arg 
Ile923Val 
Ala946Thr 
C N 
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A persistent infection can also lead to functional impairment of the beta cell such as 
suppression of insulin release [167, 171, 172]. 
Molecular mimicry has also been suggested. This theory proposes that similarities in the 
sequence between virus epitopes and beta cell antigens leads to a cross-reactive T cell 
response that eliminates not only virus but also beta cells [178]. Resemblance has been found 
between enterovirus protein 2C and host protein GAD65 that supports this theory [179, 180].  
Bystander activation is yet another proposed mechanism. In this scenario, auto-reactive T 
cells specific for beta cell antigens are activated and initiate an autoimmune attack on the 
pancreatic beta cells. An infectious agent may be involved in this scenario. A persistent 
infection may lead to a low-grade inflammatory response thus creating a cytokine milieu, 
which attracts T cells resulting in beta cell destruction [178]. 
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2 AIMS 
The overall aim with this thesis was to gain a better understanding of the immune response 
against enterovirus infections. Moreover, the aim was to unravel the mechanisms used by the 
virus to evade the immune system. 
 
Specific aims: 
• To study the role of the intracellular receptor MDA5 in host survival and regulation of 
CVB replication (Paper I) 
• To assess the human pancreatic islet response to CVB infection (Paper II) 
• To study whether a polymorphism in IFIH1 dictates the antiviral response to CVB 
(Paper II) 
• To determine if type III IFNs are expressed upon a CVB infection (Paper III and 
IV) 
• To study if type III IFNs elicit a biological response and reduce CVB replication in 
human pancreatic islets (Paper III) 
• To study whether type III IFNs regulates permissiveness to CVB infection in primary 
human hepatocytes (Paper IV) 
• To study if CVB has evolved mechanisms to evade the type III IFN response (Paper 
V) 
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3 MATERIAL AND METHODS 
3.1.1.1 Animals 
In Paper I, mda5-/- and wild-type animals on two different backgrounds, C57BL/6 and 
129/SvJ were used. The animals were bred and housed under specific pathogen free 
conditions at Washington University School of Medicine, St. Louis, USA. All animal 
experiments were conducted in accordance with the institutional guidelines for animal care 
and use and with appropriate ethical permission. 
3.1.1.2 Primary cells 
Pancreatic islets isolated from human organ donors were used in Paper II and III. The islets 
were isolated at Uppsala University within the Nordic Network for islet transplantation. 
Primary human hepatocytes were isolated at Karolinska University Hospital and used in 
Paper IV. Informed consent was obtained from all donors or their relatives. A benefit of 
using primary cells isolated from human donors is that they display a diverse genetic 
variation and may provide a better representation of the population compared to cell lines and 
animal models. However, there are also limitations associated with the use of primary cells. 
Due to the varying genetic backgrounds and characteristics of the donors (such as age and 
previous infections) the results are likely to have a larger variation. Also, it is important to 
remember that the time from isolation to experimental use and the isolation process itself can 
affect the quality of the cells. The quality of the pancreatic islets was tested by measuring the 
insulin release (stimulation index (SI)) in response to glucose. Only islets with a SI above 4 
were used to assess the innate immune response to Coxsackievirus infection in Paper II. 
3.1.1.3 Cell lines 
HeLa, HepG2 and Huh7.5 cells have been used throughout the studies presented in this 
thesis. HeLa cells were chosen since it is a cell line that is widely used and well 
characterized. HepG2 and Huh7.5 cells are derived from the liver and were used in Paper IV 
to determine whether type III IFNs protects against a Coxsackievirus infection. 
3.1.1.4 Virus strain 
The CVB3-Nancy strain was used in all studies described in this thesis. This virus strain was 
chosen since it is well characterized and widely used in the field. Also, the CVB3 strain has 
been associated with several diseases such as T1D and myocarditis. HeLa cells were used for 
propagation and titration of the virus.  
3.1.1.5 Virus detection 
Throughout this thesis, several methods were used for detection of CVB3 replication. During 
viral replication the protein VP1 is expressed and the presence of this protein in infected cell 
were detected using Western blot and/or flow cytometry. To measure the amounts of 
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infectious virus particles in tissues (Paper I) or culture supernatants (Paper II – V), plaque 
assays were performed.  
3.1.1.6 Real time RT-PCR 
Real time RT-PCR provides a sensitive and powerful tool to analyze changes in mRNA 
expression. Compared to conventional PCR, real-time RT-PCR is an efficient method used to 
quantify gene expression. Real-time RT-PCR was used in all of the papers included in this 
thesis, and in addition it was also used to perform the PCR array described in Paper III. 
Throughout this thesis, relative RT-PCR was used to compare the expression levels between 
sample. To normalize the sample, the expression levels of the gene of interest were always 
compared with an internal control. Samples that displayed cycles above 35 cycels was 
considered below detection limit. Real-time RT-PCR was also used to genotype the donors 
used in Paper II. This assay is based on fluorescent probes specific for the polymorphism in 
IFIH1 (Ala946Thr). 
3.1.1.7 Western blot 
Western blot was used in Paper II, II and V to measure the protein expression levels 
following infection with Coxsackievirus or IFN-treatment. Western blot was used as a 
complement to the mRNA analysis to confirm the upregulation of a gene also on protein level 
in Paper III. In addition, Western blot was used to identify proteins that are targeted by 
CVB3 Paper V. This technique was also used to measure the phosphorylation status of IRF3 
in Paper V. 
3.1.1.8 Immunohistochemistry and immunofluorescence 
Immunohistochemistry was used in Paper I to detect tissue damage and inflammation in 
organs. Immunohistochemistry together with immunofluorescence was used to detect the 
cellular localization of the IFNλR in Paper III, which was carried in collaboration with Dr. 
Sarah Richardson and Prof. Noel Morgan at the University of Exeter, United Kingdom. 
3.1.1.9 ELISA 
ELISA was used to detect the amounts of secreted IFNα in Paper I and secreted CXCL10 in 
Paper III. ELISA and a sensitive bioassay were also used to measure accumulation of type I 
and type I IFNs and III IFNs in culture supernatants from CVB3 infected human pancreatic 
islets, but these analyses failed to detect IFNs (data not shown). 
3.1.1.10 Measurement of cytopathic effects  
In Paper IV we performed a 96-well assay to measure the cytopathic effect after a 
Coxsackievirus infection. This assay was modified from a previously described protocol to 
examine the protective effect of type III IFNs [181].  
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4 RESULTS AND DISCUSSION 
4.1 RECOGNITION OF COXSACKIEVIRUS 
4.1.1 The role of MDA5 in the host response to a Coxsackievirus infection 
The ability to recognize a virus infection is crucial for the initiation of a proper immune 
response. PRRs such as TLRs and RLRs play an important role in sensing viral structures and 
inducing the expression of IFNs. Previous studies have identified a role for several TLRs in 
sensing Coxsackieviruses [17, 110, 111, 115, 116]. In 2006 Smyth et al reported that 
polymorphisms in the gene encoding the viral sensor MDA5 were associated with an 
increased risk for T1D development [139], a finding that has provided a potential explanation 
for the association seen between enterovirus infections and susceptibility to T1D. However, 
whether MDA5 was of importance in recognizing Coxsackieviruses was not known. The aim 
of Paper I was, therefore, to address the role of MDA5 during a CVB3 infection. 
To determine the role of MDA5 in CVB infections, mice that were deficient in MDA5 
(mda5-/-) and wild type (wt) controls were challenged with CVB3. We found that mice 
lacking mda5 that were on a C57BL/6 (B6) background succumbed early to CVB3 infection 
while most wt mice survived (Paper I, Figure 1A). Mice deficient in MDA5 also displayed a 
marked disability in their control of virus replication early after infection (Paper I, Figure 
2A), suggesting that MDA5 controls viral replication early during infection. Binding of viral 
RNA to MDA5 triggers the induction of IFNs. Since a rapid expression of IFNs is important 
for controlling a Coxsackievirus infection [118, 119] we wished to examine the expression of 
IFN and IFN-inducible genes in the animals. We found that wt mice had an increased 
production of IFNα in serum at 48 h post infection (Paper I, Figure 3A). At this time point, 
CVB3-infected mda5-/- mice also had an increased production of IFNα, although the 
induction was lower compared to infected wt animals (Paper I, Figure 3A). An increased 
induction of IFNβ mRNA was detected in the liver and pancreas of both mda5-/- and wt mice 
post CVB3 infection (Paper I, Figure 3B). There was also an increased expression of OAS1a 
and CXCL10 in these organs (Paper I, Figure 3C-D). Finally, the inability to control early 
viral replication led to severe tissue damage in the liver and exocrine pancreas in the mda5 
deficient mice (Paper I, Figure 4 A-C).  
The findings in Paper I show that MDA5 is important for controlling early CVB3 replication 
and that an inability to appropriately regulate the virus has devastating effects on the host. 
Our results showing that MDA5 is important for survival upon a CVB3 infection are similar 
to those reported by Wang et al [34]. There are however, some differences between the 
studies. Wang et al report that MDA5 is important for survival after a CVB infection in mice 
on 129/SvJ background, whereas our results show no difference in survival rates post CVB3 
infection on this genetic background (Paper I, Figure 1B). This difference may be explained 
by the higher dose of virus used in the study performed by Wang et al. Our results do, 
however show that a lack of MDA5 in 129/SvJ mice leads to tissue damage long after the 
virus is cleared (Paper I, Figure E). 
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Our results also show that MDA5 is not absolutely required for induction of type I IFNs. 
Furthermore, the finding that mice lacking MDA5 are still able to induce the expression of 
type I IFNs upon CVB3 infection suggests that additional receptors may also recognize 
Coxsackievirus. So far, a role for RIG-I in Coxsackievirus infection has not been described, 
however TLR3, TLR4, TLR7 and TLR8 are potential receptors that may also recognize 
Coxsackieviruses [14, 17, 110, 115]. It is likely that the induction of IFNα seen in the mda5-
/- mice is mediated by one or several of these TLRs. Furthermore, although we detect IFNα 
in the serum of mda5-/- at 48 h post infection, it is interesting to note that the levels are lower 
compared to wt mice. This suggests that MDA5 is important for the early induction of type I 
IFNs but other receptors may have a role later. Since type I IFNs are critical in limiting 
CVB3 replication, it is possible that the slight reduction in IFN levels lead to increased virus 
titers and as a consequence of this, severe tissue damage. In Paper III and IV, we identified 
a protective role for type III IFNs in CVB3 infection and it would be interesting to see 
whether the lack of MDA5 also influence the induction of type III IFNs. 
Several polymorphisms in IFIH1 that regulates susceptibility to T1D have been identified 
[138, 139]. Two studies recently reported that overexpression of MDA5 leads to the 
development of autoimmune symptoms [182, 183]. This suggests that a reduced function of 
MDA5 is protective in autoimmune diseases. In our study, we saw no signs of T1D 
development in the mda5-/- animals. However, we found that MDA5 plays an important role 
in the host defense against a Coxsackievirus infection, which can have implications for how 
MDA5 regulates virus-induced T1D. Based on our result that a lack of MDA5 leads to 
uncontrolled viral replication, one can speculate that a strong immune response will protect 
against a virus infection. Coxsackievirus replication initially takes place in the intestine, and 
an inability to block virus here may increase the risk for the infection to spread to other 
organs, such as the pancreas. A reduced capacity to control the virus infection may also lead 
increased number infections and also more severe infections. Interestingly, enterovirus 
infections are more commonly found among persons with T1D than healthy controls [184]. A 
strong immune response can however also lead to the activation of auto reactive T cells that 
initiate an autoimmune attact on the host [179]. On the other hand, a weak early response 
may lead to that the virus can replicate and spread within the body. This can result in an 
increased expression of antiviral genes in the target organs and an increased activation of the 
immune response, which may contribute to the activation of self-reactive T-cells and 
subsequent induction of autoimmunity. This scenario is supported by the results in (Paper I, 
Figure 3), which show that the mda5-/- animals display increased levels of ISGs in target 
organs.  
In summary, in Paper I we show that MDA5 play an important role in controlling CVB3 
infection, especially early in the infection. Moreover, we show that MDA5 is not absolutely 
required for induction of type I IFNs.  
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4.1.2 A polymorphism in IFIH1 modulates the antiviral response 
Infections with enteroviruses, especially those with Coxsackieviruses have been linked to 
T1D in several studies [161, 163]. In Paper I we found that MDA5 plays an important role in 
recognizing and controlling an infection with CVB3.  Several polymorphisms in IFIH1 have 
been associated with T1D, however how these SNPs affect the ability of MDA5 to recognize 
Coxsackieviruses and induce an innate immune response is not currently known. The aim 
with Paper II was to study the human islet response to a Coxsackievirus infection and 
determine if a polymorphism in IFIH1 affects the antiviral response. 
We started by examining the islets antiviral response against a Coxsackievirus infection. We 
found that the islets responded to a CVB3 infection by inducing the expression of type I and 
type III IFNs (Paper II, Figure 1A and 2B). We made an attempt to measure secreted IFNs 
both using ELISA and a bioassay, however the levels were below detection limit (data not 
shown). Secreted IFNs act in an autocrine and a paracrine manner to induce the expression of 
IFN-inducible genes [185] and measuring the expression of these genes can be used as an 
indirect measurement of IFN production. In response to CVB3 infection, the islets strongly 
induced the expression of genes involved in viral recognition (MDA5, RIG-I and TLR3) and 
antiviral defense mechanisms (CXCL10 and MxA) (Paper II, Figure 1B-C).  
The polymorphism Ala946Thr (rs1990760) in IFIH1 shows the strongest association with 
T1D. The risk allele of this polymorphism encodes threonine (Thr, here denoted “TT”) in 
codon 946, whereas the non-predisposing allele encodes alanine (Ala, here denoted “CC”) in 
this position [139]. To determine if this polymorphism affects the islet’s ability to induce an 
antiviral response after Coxsackievirus infection, we genotyped the donors included in the 
study. Surprisingly, our cohort did not contain any donors with the protective CC-genotype. 
Instead, the cohort consisted of similar numbers of donors carrying the TT- or TC-genotype 
(Paper II, Table 1). After dividing the donors according to genotype, we found no difference 
in the induction of either type I and type III IFNs between the two genotypes. However, 
donors carrying the TT-genotype showed a trend towards lower amounts of type III IFNs 
compared to the TC-genotype (Paper II, Figure 2B). Next, we analyzed the induction of 
IFN-stimulated genes with respect to the polymorphism in IFIH1. Intriguingly, after infection 
with CVB3 a lower induction and/or expression level of MDA5, RIG-I and TLR3 was seen 
in donors carrying the risk TT-genotype compared to the TC-genotype (Paper II, Figure 3).  
It is important to highlight that there are, however, some limitations in Paper II. The first is 
that our cohort is rather small due to the scarcity of human islets donors. Secondly, we lack 
donors with the protective CC-genotype. Examples of polymorphisms exist where the 
heterozygous mutation is associated with a higher or lower effect than the homozygous 
mutations, a phenomena known as molecular heterosis [186]. In fact, a study by Cinek et al 
found that the presence of enterovirus in blood from T1D patients was more frequent in 
patients carrying the TC-genotype of the Ala946Thr polymorphism [187]. Therefore, one 
should be careful in drawing conclusions regarding how donors with a CC-genotype would 
respond to infection and furthermore how this relate to the TT-donors. Thirdly, we only study 
 20 
the time point 48 h after infection. Assessing gene induction following infection at other time 
points may increase the chance of finding an association between the Ala946Thr 
polymorphism and the human islets response upon infection.  
A large number of studies support the association between polymorphisms in IFIH1 and 
autoimmune diseases such as T1D [139-144], SLE [147, 148], autoimmune thyroid disease 
[150] and Aicardi-Goutiers syndrome [183, 188]. Interestingly, a recent study found an 
association between the 946Thr polymorphism in IFIH1 and the development of dilated 
cardiomyopathy [189]. In a similar manner to T1D, infections with enteroviruses have been 
implicated in the pathogenesis dilated cardiomyopathy [190]. 
Since the discovery of the association between polymorphisms in IFIH1 and the development 
of T1D, several studies have attempted to elucidate the mechanism by which the 
polymorphisms affect risk for disease development. Nejentsev et al identified four rare 
variants of IFIH1 that are associated with protection against T1D [138]. These variants 
correlated with lower expression levels of MDA5 and they displayed a reduced ability to bind 
dsRNA, implying that diminished expression and function is protective against T1D [151, 
152]. In line with this, Liu et al reported that the predisposing 946Thr polymorphism was 
associated with increased basal expression of MDA5 [142]. However, others failed to 
reproduce this finding [191, 192] and in addition, we did not find an association between the 
Ala946Thr polymorphism and basal expression levels of MDA5 in human islets (Paper II, 
Figure 3). A recent study found that the 946Thr variant of MDA5 was constitutively active 
[182]. In Paper II, we measured basal expression (i.e. uninfected islets) levels of IFNs and 
IFN-stimulated genes in human islets carrying the TT and TC genotypes and found no 
difference in their expression in the absence of a CVB3 infection (Paper II, Figure 2B). In 
parenchymal cells such as human islets, the basal expression of MDA5 is very low [66, 78] 
and Paper II, Figure 1D) which may explain why we fail to detect a difference in basal 
expression of IFNs between the two genotypes. Immune cells such as DCs, however, may 
express higher levels of MDA5 and it is possible that a constitutively active variant might be 
detected with greater ease in these cell types. Immune mediated diseases such as SLE and 
T1D have been associated with an IFN-signature [182, 193, 194] and a polymorphism in 
IFIH1 that leads to a constitutively active protein in combination with other predisposing 
genes may contribute to this IFN-signature. Interestingly, Funabiki et al also showed that the 
946Thr variant of IFIH1 is unable to respond to an infection with EMCV with the induced 
expression of IFNs [182]. We show that the donors expressing the TT-genotype respond with 
lower expression of type III IFNs and IFN-stimulated genes after infection with CVB3 
compared to donors carrying the TC-genotype (Paper II, Figure 2B, 3 and 4), which may 
indicating that the TT-donors are less responsive.  
To summarize our findings in Paper II, we show that the Ala946Thr polymorphism affects 
the ability of human islets to respond to a CVB3 infection. We found that the risk genotype 
(TT) is associated with a lower induction of viral sensors after infection compared to the TC-
genotype. 
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4.2 PROTECTIVE EFFECT OF TYPE III INTERFERONS 
4.2.1 Protective effect in human islets 
Restriction of early viral replication is heavily dependent on the induction of IFNs. The type 
III IFNs are the most recently identified IFN-family and they have been shown to protect 
against infection with various viruses [84, 85, 195]. This protective effect however, is limited 
to a narrow subset of cell types [62, 63]. In Paper III, we wished to investigate whether 
human islets were able to respond to type III IFNs and if such stimuli render islets resistant to 
a Coxsackievirus infection. 
We started by determining whether human islets express type III IFNs following a 
Coxsackievirus infection. We found that the islets induced expression of IFNλ1 and IFNλ2 
(Paper III, Figure 1A). The ability of a cell to respond to type III IFNs is dependent on the 
expression of IFNλR [44, 45]. To determine if human islets are able to respond to type III 
IFNs, we first examined whether islets express the IFNλR. Human islets were shown to 
express both receptor subunits at mRNA level, although the levels varied amongst the donors 
(Paper III, Figure 2A). To further evaluate the cellular localization of the subunits, we 
studied pancreas sections from healthy subjects using immunofluorescence. The expression 
IL-10R2 was detected in alpha- and beta-cells but not in delta cells, whereas expression of 
IFNλR1 was found only in alpha cells (Paper III, Figure 2B). Although our studies cannot 
exclude a low expression level (i.e. below the detection limit of our assay), the finding that 
beta cells do not express IFNλR, suggests that beta cells are unable to respond or have a low 
response to type III IFNs. Interestingly, it has been shown that enteroviruses preferentially 
replicate in beta cells and not alpha cells [163, 196]. However, whether beta cells have the 
ability to induce the expression of the IFNλR upon Coxsackievirus infection or other stress 
inducing stimuli, as has been shown for Hepatitis C virus [197], remains to be established.  
Expression of both IFNλR subunits in at least some of the cells in the islets indicated that the 
islets had the ability to respond to type III IFNs. To gain an insight into what genes are 
upregulated upon type III IFN stimulation, we treated islets with IFNλ1, IFNλ2 or IFNα. 
After six hours the upregulation of 88 genes that are known to be modulated by IFNα and -β 
was evaluated using a PCR array.  In agreement with other studies [64, 65] we found that 
IFNλ1 and IFNλ2 induced expression of a similar set of genes as IFNα (Paper III, Figure 3). 
However, IFNα induced a greater number of genes compared to the type III IFNs (Paper III, 
Figure 3). In addition, we confirmed the upregulation of some of the genes at the protein level 
such as MDA5 and RIG-I (Paper III, Figure 4).  
Due to our observation that a number of genes with antiviral activity are upregulated after 
type III IFN treatment in human islets, we next tested whether the type III IFNs could prevent 
CVB replication in human islets. Viral replication was measured using two techniques: by 
determining the protein expression of VP1 using Western blot and by measuring accumulated 
virus titers in the supernatant by plaque assay. Infected islets had a high expression of VP1 
(Paper III, Figure 5A). However, treatment with IFNλ1 and IFNλ2 before infection with 
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CVB3 reduced the expression of VP1 to levels below the detection limit (Paper III, Figure 
5A). In addition, lower titers of replicating virus were detected in the supernatants of islet 
pretreated with IFNλ1 or IFNλ2 before infection (Paper III, Figure 5B). 
IFNs are important for protecting pancreatic islets against virus infection [66, 78, 119]. Mice 
harboring beta cells that cannot respond to type I IFNs rapidly develop diabetes following a 
CVB infection [117]. Our findings in Paper III suggest that in addition to the type I IFNs, 
type III IFNs also contribute to this protection. Our study, however does not provide a 
mechanistic insight into the proteins which are important in protecting islets against a CVB3 
infection. Nonetheless, the gene array results can give some hints. For example, PKR and 
OAS were induced by type III IFNs. Activation of PKR leads to the attenuation of protein 
translation, while OAS generates 2’5’ oligoadenylate, which activates RNase L as a means to 
enhance degradation of viral RNA. The involvement of both proteins in protection against 
CVB infection has been demonstrated [71]. Another gene that was upregulated by type III 
IFNs was the chemokine CXCL10. CXCL10 has a key role in the immune system were it can 
manipulate NK and T cell trafficking and cause effector functions [198]. Using a mouse 
model for virus induced myocarditis, it was shown that CXCL10 played an important role in 
limiting Coxsackievirus infection in the heart [199]. However, CXCL10 can also have a 
negative effect via contributing to autoimmune diseases by attracting autoreactive T cells to 
the site. In line with this, it has been shown that expression of CXCL10 in pancreatic beta 
cells accelerates the development of T1D [200]. 
To summarize, in Paper III we show that human islets respond to a Coxsackievirus infection 
by inducing the expression of type III IFNs. Moreover, islets stimulated with type III IFNs 
upregulate genes with antiviral activity and render the cells resistant to Coxsackievirus 
infection.  
4.2.2 Protective effect in hepatocytes 
In Paper III we found that type III IFNs have a protective effect against Coxsackievirus 
infection in pancreatic islets. Coxsackieviruses however, have a broad tissue tropism and 
infection is not limited to just the pancreas but other organs such as the heart and liver are 
also targeted [92]. Especially neonates and young children are at risk of developing 
complications following a Coxsackievirus infection. On rare occasions, the infection reaches 
the liver and can cause hepatitis, which may progress to acute hepatic necrosis associated 
with liver failure and coagulopathy [201, 202]. Factors regulating susceptibility to 
Coxsackievirus infections of the liver remain poorly understood and whether type III IFNs 
play a role was currently unknown. Based on our observations made in Paper III we 
hypothesized that type III IFNs could have an important role in protecting hepatocytes from 
infection. In Paper IV we aimed to address this hypothesis by testing whether type III IFNs 
protect human hepatocytes against a Coxsackievirus infection. 
To our knowledge no studies had been conducted whereby primary human hepatocytes were 
infected with Coxsackievirus in vitro, so the first question we asked was whether hepatocytes 
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were permissive to CVB infection. We found that hepatocytes were susceptible to infection 
with CVB as replicating virus was detected, as shown by the presence of intracellular VP-1 in 
the hepatocytes (Figure 4). Moreover, infectious viral particles were released from the cells 
into the supernatant and this together with an increased cell death indicated that the virus 
underwent a complete replication cycle and resulted in cell lysis (Figure 4, and data not 
shown). Infecting the cells with a higher dose of virus led to increasing titers in the 
supernatant (Figure 4), and maximum titers were found at 24 h post infection (Paper IV, 
Figure 1).  
 
Figure 4. CVB3 infects and replicates in primary human hepatocytes. A. Primary 
hepatocytes were infected with CVB3 and at 24 h post infection, total protein was isolated 
and the expression of VP1 was measured using Western blot. Actin was used as loading 
control. B. Primary human hepatocytes were infected with CVB3 at an MOI of 1, 10 or 100. 
At 48 h post infection, viral titers were measured in the supernatant using plaque assay. (Lind 
K and Flodström-Tullberg M, unpublished results). 
Hepatocytes have previously been shown to express type III IFNs upon infection with 
Hepatitis C virus [203, 204]. Together with our findings in Paper III, showing that CVB 
induce type III IFNs in human islets, we hypothesized that CVB infection of primary 
hepatocytes would induce the expression of type III IFNs. Indeed, hepatocytes responded to 
the infection by inducing the mRNA expression of IFNλ1 and IFNλ2 (Paper IV, Figure 1B). 
In agreement with other studies [87, 205], we found that hepatocytes express the IFNλR and 
induce the expression of ISGs in response to stimulation with IFNλ1 and IFNλ2 (Paper IV, 
Figure S1 and 3A). Importantly, we found that pretreatment of the cells with IFNλ1 or IFNλ2 
resulted in protection against infection with CVB3 (Paper IV, Figure 3B). 
In Paper III and IV we found that IFNλ1 and IFNλ2 protect cells from a Coxsackievirus 
infection. One limitation with these studies is that they did not include IFNλ3. The sequence 
homology between IFNλ2 and IFNλ3 is around 96% suggesting that the two would have 
similar potency [45]. However, IFNλ3 has been shown to have a more potent protective 
effect against EMCV (belongs to the enterovirus genus) than IFNλ1 and IFNλ2 [206]. In 
addition, a recent study found that IFNλ3 induced a greater induction of IFN-inducible genes 
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compared two IFNλ1 and IFNλ2 [207]. Extending the studies to also include IFNλ3 would 
therefore be of interest. 
The results presented in Paper III and IV demonstrate that infected cells express type III 
IFNs upon a Coxsackievirus infection. Our findings also indicate that this group of IFNs 
induce an antiviral state in cells and participates in the defense against CVB by limiting viral 
replication. These results support the notion that pancreatic beta cells and hepatocytes can 
regulate their own permissiveness to Coxsackievirus infection. An increasing number of 
reports suggest that the role of type III IFNs is to protect mucosal surfaces from pathogenic 
viruses [85, 195]. Interestingly, a recent study identified a non-redundant role of the type III 
IFNs in protecting intestinal epithelial cells from rotavirus infection [85]. Coxsackievirus 
normally infects the host via the fecal oral route and initial replication occurs in the epithelial 
cells of the intestine. One can speculate that type III IFNs would play an important role in 
limiting Coxsackievirus entry into the host by preventing infection of the epithelial cells 
lining the intestine. Studies examine the role of type III IFNs in Coxsackievirus infections of 
the intestine are warranted. 
To summarize, the findings in Paper IV shows that type III IFNs protect primary human 
hepatocytes from a Coxsackievirus infection.  
4.3 COXSACKIEVIRAL IMMUNE EVASION STRATEGIES  
The importance of type I IFNs in the defense against a Coxsackievirus infection is underlined 
by the existence of evasion strategies developed by the virus to impede the immune response 
[208]. In Paper III and IV, we found that type III IFNs limit Coxsackievirus replication in 
pancreatic islets and also in primary hepatocytes. These observations led us to hypothesize 
that Coxsackieviruses have evolved mechanisms to also evade the type III IFN response. Our 
aim in Paper V was therefore to determine whether Coxsackievirus has developed 
mechanisms to inhibit the expression of type III IFNs.  
We started by determining whether HeLa cells induced the expression of type III IFNs upon 
infection with CVB3. As a positive control, the cells were treated with the viral mimic poly 
I:C. Treatment with poly I:C, led to an increased in the expression of type III IFNs, 
demonstrating that the cells responded to an virus infection (Paper V, Figure 1A). 
Interestingly, we did not detect any IFNλ1 or IFNλ2 mRNA expression following infection 
with CVB3 (Paper V, Figure 1A). In order to establish whether the virus is able to inhibit the 
induction of type III IFNs, we infected cells with CVB3 prior to treatment with poly I:C.  
Recognition of Coxsackievirus infection has been shown to be dependent on both MDA5 and 
TLR3 [33, 34, 110, 111] and Paper I. To determine if the virus were able to inhibit both 
these pathways we delivered poly I:C by two different routes: via transfection (where it is 
sensed by TLR3 [15, 209]) or exogenously (as sensed by MDA5 [209, 210]. We found that 
infection with CVB3 strongly inhibited the induction of type III IFNs following both the 
exogenous application and transfection of poly I:C (Paper V, Figure 2), indicating that the 
virus blocks both MDA5- and TLR3-signalling.  
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Induction of type III IFNs is dependent on the activation of the transcription factor IRF3 [57, 
58, 60]. Activation of IRF3 is regulated via hyperphosphorylation of the protein [211]. We 
found that transfection of poly I:C led to hyperphosphorylation of IRF3. In contrast, this was 
not detected after infection with CVB3 (Paper V, Figure 3A). The finding that IRF3 was not 
fully activated following CVB3 infection indicated that signaling molecule(s) upstream of 
IRF3 were targeted. Indeed, we found that the expression of TRIF (the adaptor protein 
utilized by TLR3, Figure 1) declined in CVB3-infected cells (Paper V, Figure 2B-C). 
Moreover, we found that the MDA5-pathway was inhibited during CVB3 infection, as 
indicated by the reduction of IPS1-expression (the adaptor protein utilized by MDA5, Figure 
1) during the course of infection (Paper V, Figure 2B-C). In addition, the expression of 
MDA5 and RIG-I were lower following CVB3 infection (Paper V, Figure 2B).  
At least two strategies have been described for how enteroviruses cleave signaling molecules 
important for the induction of IFNs. Either, the infection can activate caspases that cleaves 
the protein. Subsequently, the protein is degraded by the proteasome [212] or proteins can be 
targeted and degraded by virally encoded proteases [103, 213]. We started by investigating 
the role of capsases and the proteasome during a Coxsackievirus infection, by infecting HeLa 
cells in the presence of caspase or proteasome inhibitors. As seen previously, infection with 
CVB3 led to reduced expression of both TRIF and IPS1 and this occurred in the presence of 
inhibitors (Paper V, Figure 4). Thus, we concluded that the decreased expression of TRIF 
and IPS1 was independent of both caspases and proteasomal degradation. We continued to 
investigate the second possible strategy: namely the targeting of host proteins by virally 
encoded proteases. Coxsackieviruses encode two proteases, 2A and 3C. By constructing 
vectors containing 2A or 3C and expressing these in HeLa cells, we were able to study their 
possible role in blocking the expression of IFNs. We found that, expression of 2A inhibited 
the poly I:C-induced expression of IFNλ1 and IFNλ2 (Paper V, Figure 5). Moreover, 
expression of 2A led to decreased the levels of TRIF and IPS1 (Paper V, Figure 6). We 
found no inhibitory effect on type III IFN induction after expressing 3C nor did we see a 
decrease in the expression of TRIF and IPS1 (Paper V, Figure 6).  
Type III IFNs were identified in 2003 [44, 45] and so far, only a few reports have been 
published that describe the viral evasion strategies which target type III IFNs [58, 214-216]. 
The results in Paper V demonstrate that Coxsackieviruses have also evolved inhibitory 
mechanisms to block the induction of type III IFNs. Furthermore, our study provides insight 
into the strategy by which the virus evades this host antiviral immune response. We found 
that the activation of IRF3 was severely inhibited during a Coxsackievirus infection, which is 
in agreement with other reports [102, 106]. Furthermore, we found that the expression of both 
TRIF and IPS1 were reduced following a CVB3 infection. TRIF and IPS1 act as adaptor 
molecules important for the induction of IFNs, and targeting these molecules may be a 
strategy used by the virus to block type III IFNs. However, coxsackieviruses are known for 
inhibiting several host functions such as shutting of host transcription and translation [103-
105]. Most likely all these inhibitory actions are acting together to efficiently block IFN 
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induction. Furthermore, the exact mechanism that the virus uses to inhibit the induction of 
type III IFNs remains to be determined. 
Moreover, we also show that the expression of MDA5 and RIG-I were reduced after 
infection with CVB3. The fact that CVB3 also targets RIG-I was somewhat surprising since 
Coxsackieviruses do not bear a 5’ triphosphate and therefore, it would be unexpected for 
them to be recognized by RIG-I. However, the finding that CVB3 reduces the expression of 
RIG-I, suggests that it might play a so far unidentified role during Coxsackievirus infection. 
During the preparation of Paper V, two studies reported that CVB-encoded proteases target 
MDA5- and TLR3-pathways [102, 106]. Our findings support the results described by Feng 
et al, which show that 2A targets IPS1, and similar observations have been made with the 2A 
protease from poliovirus and Enterovirus 71 (both belonging to the enterovirus genus) [102, 
217]. In addition, our results demonstrate that TRIF is targeted by 2A (Paper V, Figure 6). 
This is in contrast to the findings seen by Mukherjee et al, which show that TRIF is cleaved 
by 3C [106].  
In Paper III and IV we found that a Coxsackievirus infection induces the mRNA expression 
of type III IFNs in primary cells, which may seem contradictive to the results presented in 
Paper V. It is however difficult to estimate the level of type III IFNs detected in Paper III 
and IV as we do not have a suitable positive control to compare with, such as poly I:C or a 
modified virus that lacks the ability to inhibit the induction low levels of IFNs. In addition, in 
Paper II we measured the levels of secreted IFNs in the supernatant using two sensitive 
methods namely, ELISA and a bioassay. However, with both methods the levels of IFNs 
were below detection limit, indicating that Coxsackievirus induce very low levels of IFNs in 
primary cells. We can nonetheless conclude from Paper I that a Coxsackievirus infection in 
vivo leads to the induction of IFNs. Although the levels were not sufficient to efficiently 
block viral replication (Paper I, Figure 2B).  
In summary, we show in Paper V that Coxsackieviruses have developed mechanisms 
through which they can interfere with the induction of type III IFNs. 
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5 CONCLUDING REMARKS 
The aim of this thesis was to expand our understanding of the interplay between host and 
virus during an enterovirus infection. Our focus has been on the innate immune system and 
the proteins that are important for recognizing and controlling a Coxsackievirus infection.  
Our findings in Paper I highlight the role of MDA5 as an important protein that is involved 
in controlling the outcome of Coxsackievirus infections. Infections with Coxsackieviruses 
have been associated with severe diseases and have in addition been implicated in the 
development of T1D. Several polymorphisms in IFIH1, the gene encoding MDA5, have been 
associated with the development of T1D. In Paper II, we show that the Ala946Thr 
polymorphism in IFIH1 affects the ability of human islets to induce the expression of type III 
IFNs and IFN-inducible genes after a Coxsackievirus infection. Induction of IFNs is 
important both for protecting target cells from a virus infection and for limiting the 
replication of virus in cells that are already infected. In Paper III and IV we found that type 
III IFNs contribute to the antiviral defense initiated against Coxsackieviruses. Our results in 
Paper III show that human islets respond to type III IFNs by inducing genes with known 
antiviral effects. In addition, type III IFNs render human islets resistant to Coxsackievirus 
infection. Furthermore, in Paper IV we show that type III IFNs also protect primary human 
hepatocytes against an infection with Coxsackievirus. Due to the potent protective effect of 
IFNs, viruses have evolved multiple strategies to circumvent the immune response and in 
Paper V, we describe a mechanism utilized by Coxsackieviruses to prevent the induction of 
type III IFNs. This identifies a new strategy, through which Coxsackieviruses evade the 
immune response and at the same time provides insight into the proteins, which are important 
in combating a Coxsackievirus infection. 
The studies of which this thesis is comprised, contribute to a deeper understanding of the 
interplay between host and pathogen during an enterovirus infection. Our findings emphasize 
the importance of the innate immune system in controlling Coxsackievirus infections. 
Increasing our knowledge of the interactions between Coxsackieviruses and the immune 
system will hopefully contribute to the development of therapeutic agents that could prevent 
diseases associated with such infections. 
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